Agenda

25% (minimum) of each presentation will involve interactive learning. All presentations witll be followed by a Q & A period.

0730 Breakfast and Registration
Toronto Foyer
0830 Welcome and Opening Remarks
Sean Balmain
Toronto I & II
Act 1: Early Diabetes
0840 The Truth about Prediabetes and Vascular Risk
Caroline Kramer
Toronto I & II
0905 The Skinny on Phamacological Weight Loss Therapies
Alice Cheng
Toronto I & II
0930 Nutrition Quick Hits: How to provide cultural specific dietary advice
Karen Blekaitis
Toronto I & II
0955 Panel Discussion
Toronto I & II
1015 Refreshment Break
Toronto Foyer
Act 2: Progression of Diabetes
1035 Top 5 Diabetes Papers of 2019 for the Cardiologist
Jeremy Gilbert
Toronto I & II
1100 Cardiovascular Risk Reducuction: What can be achieved by lowering blood sugar
Gary Lewis
Toronto I & II
1125 Hypoglycemia and Cardiac Events.: Is there really a link?
Harpreet Bajaj
Toronto I & II
1150 Pannel Discussion
Toronto I & II
1210 Lunch (provided) and Exhibits
Toronto Foyer
Act 3: Complications of Diabetes
1310 Diabetes Rehab: What are the benefits / Exercise as a tool for managing CV compications of DM
Paul Oh
Toronto I & II
1335 Revascularization Treatment in Those with Diabetes
Mike Farkouh
Toronto I & II
1400 Antiplatelet Agents Through the Ages: Does it apply to those with diabetes?
Peter Lin
Toronto I & II
1425 New Treatments for Diabetic Nephropathy
James Scholey
Toronto I & II
1445 Pannel Discussion
Toronto I & II
1500 Refreshment Break
Toronto Foyer
Interactive Breakout Cases 1 (choose one)
1515 Non-Insulin Based Therapies: What comes next after Metformin
Phillip Segal
To be Announced
1515 When (and when not) to Consider Newer Insulins
Elaine Wylie
To be Announced
1515 Quality Improvement in Diabetes
Julie Gilmour
To be Announced
1515 Psychosocial Challenges in Diabetes Care
Miranda Boggild
To be Announced
Interactive Breakout Cases 2 (choose one)
1545 Non-Insulin Based Therapies: What comes next after Metformin
Phillip Segal
To be Announced
1545 When (and when not) to Consider Newer Insulins
Elaine Wylie
To be Announced
1545 Quality Improvement in Diabetes
Julie Gilmour
To be Announced
1545 Psychosocial Challenges in Diabetes Care
Miranda Boggild
To be Announced
1615 Adjourn for the Day

 

0730 Breakfast and Registration
Toronto Foyer
0830 Welcome and Opening Remarks
Sean Balmain
Toronto I & II
Act 4: Coronary Disease and Vascular Complications
0840 Risk Stratification of Chest Pain: CT angiography or stress testing
Mini Pakkal
Toronto I & II
0905 Expanding Indications for Direct Oral Anticoagulants for Cardiovascular Disease
Eric Kaplovitch
Toronto I & II
0930 Management of Peripheral Vascular Disease in Diabetes
Tom Forbes
Toronto I & II
0955 Panel Discussion
Toronto I & II
1015 Refreshment Break
Toronto Foyer
Act 5: Valvular Heart Disease and Arrhythmia
1035 TAVR in 2020 – Patient Selection and Outcomes
Eric Horlick
Toronto I & II
1100 Bradycardia – High Risk Presentations and Pacemaker Indications
Rebecca Noad
Toronto I & II
1125 Contemporary Management of Atrial Fibrillation – From Anticoagulation to Ablation
Andrew Ha
Toronto I & II
1150 Panel Discussion
Toronto I & II
1210 Lunch (provided) and Exhibits
Toronto Foyer
Act 6: Heart Failure and Cardiac Devices
1310 Medical Therapy for Heart Failure – What do the Guidelines Say?
Mike McDonald
Toronto I & II
1335 The Lethal Combination of Heart Failure and Diabetes
Jay Udell
Toronto I & II
1400 Which Device Implant Will Benefit My Patient with Systolic Heart Failure?
Sean Balmain
Toronto I & II
1425 Panel Discussion
Toronto I & II
1445 Refreshment Break
Toronto Foyer
Interactive Breakout Cases 3 (choose one)
1500 HF-PEF Management, Case-Based Discussion
Adriana Luk
To be Announced
1500 Pragmatic Strategies for the use of SGLT2 Inhibitors in Patients with Diabetes and Cardiovascular Disease
Gary Lewis
To be Announced
1500 Combining Anticoagulant and Antiplatelet Therapy – What is the Safest Approach?
Eric Kaplovitch
To be Announced
1500 Remote Monitoring and Wearable Devices in Heart Failure Care
Heather Ross
To be Announced
Interactive Breakout Cases 4 (choose one)
1530 HF-PEF Management, Case-Based Discussion
Adriana Luk
To be Announced
1530 Pragmatic Strategies for the use of SGLT2 Inhibitors in Patients with Diabetes and Cardiovascular Disease
Gary Lewis
To be Announced
1530 Combining Anticoagulant and Antiplatelet Therapy – What is the Safest Approach?
Eric Kaplovitch
To be Announced
1530 Remote Monitoring and Wearable Devices in Heart Failure Care
Heather Ross
To be Announced
1600 Symposium Adjourns